Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

NA masthead new 1

Neurology Alert – May 1, 2022

May 1, 2022

View Archives Issues

  • Cognitive Outcomes After Mild Traumatic Brain Injury

    Mild traumatic brain injuries (mTBIs) may lead to adverse cognitive and neuropsychiatric outcomes. The pathways that lead to adverse cognitive outcomes remain to be scientifically elucidated. A prospective cohort study of 656 participants enrolled in the Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) study found that at one year, 13.5% of participants with mTBI had poor cognitive outcome compared to 4.5% of controls, highlighting the need for better understanding of the mechanisms leading to poor cognitive and functional outcomes after mTBIs and interventions to optimize cognitive recovery.

  • Does Amantadine Treatment Reduce Levodopa-Induced Dyskinesias?

    This retrospective cohort study compared the effect of amantadine on levodopa-induced dyskinesia (LID) onset with use of anticholinergics and monoamine oxidase type B inhibitors in patients with Parkinson’s disease. The authors concluded that early treatment with amantadine may delay LID onset more than treatment with other symptomatic agents.

  • Outcomes of Progressive Multifocal Leukoencephalopathy Treated with IL-7

    Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system caused by the reactivation of the JC virus. The authors of this study conducted a multi-centered retrospective observational study on 64 patients with PML who were treated with recombinant human IL-7 (RhIL-7). Overall, the one-year all-cause survival following start of RhIL-7 was 55% and similar among human immunodeficiency virus/acquired immunodeficiency syndrome, hematological malignancies, and primary immunodeficiencies.

  • Antibody Profile in Refractory Myasthenia Gravis

    In retrospective studies of patients with generalized myasthenia gravis, those who are refractory to multiple treatments have disease onset at an earlier age, are more likely to have thymic pathology, and are more likely to be double-seronegative (neither acetylcholine receptor nor muscle-specific receptor tyrosine kinase antibodies).

  • Neurodegeneration Biomarkers in Patients with Subjective Cognitive Complaints

    In individuals with subjective cognitive decline, multiple biomarkers of neurodegeneration were found to add predictive values beyond amyloid and tau biomarkers; however, the various neurodegeneration biomarkers were not equivalent and should not be used interchangeably.